BeiGene Approved to Stage $3 Billion IPO on Shanghai STAR Exchange
June 30, 2021 at 06:05 AM EDT
BeiGene of Beijing has reportedly been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai , Hong Kong and the US . According to a Caixin report, BeiGene’s propectus meets the listing conditions and information disclosure requirements of the STAR Market, but regulators asked BeiGene to explain how it will protect the interests of domestic shareholders. Founded in 2010, BeiGene develops molecularly targeted and immuno-oncology drug candidates to treat cancer. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //
